Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioCryst (NASDAQ:BCRX), Collegium Pharmaceutical (NASDAQ:COLL) and Axovant Sciences (NASDAQ:AXON).
BioCryst (BCRX)
In a report released yesterday, Maury Raycroft from Jefferies reiterated a Buy rating on BioCryst, with a price target of $8.50. The company’s shares closed yesterday at $6.39, close to its 52-week high of $6.69.
According to TipRanks.com, Raycroft is a 5-star analyst with an average return of 27.2% and a 52.8% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Atara Biotherapeutics, and Intellia Therapeutics.
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $8.83, representing a 38.2% upside. In a report issued on August 7, RBC Capital also reiterated a Buy rating on the stock with a $9 price target.
.
See today’s analyst top recommended stocks >>
Collegium Pharmaceutical (COLL)
In a report released today, David Steinberg from Jefferies reiterated a Buy rating on Collegium Pharmaceutical, with a price target of $28. The company’s shares closed yesterday at $19.03.
According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 10.6% and a 50.6% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Supernus Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $31, implying a 62.9% upside from current levels. In a report issued on August 6, Janney Montgomery also maintained a Buy rating on the stock with a $27 price target.
.
Axovant Sciences (AXON)
Jefferies analyst Michael Yee reiterated a Hold rating on Axovant Sciences today and set a price target of $2.50. The company’s shares closed yesterday at $2.10, close to its 52-week low of $1.02.
According to TipRanks.com, Yee is a 4-star analyst with an average return of 6.9% and a 55.8% success rate. Yee covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Vertex Pharmaceuticals, and Acorda Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Axovant Sciences with a $6.17 average price target, implying a 193.8% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Hold rating to the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
